The evolving hemp landscape
Recent changes and clarifications around hemp laws are adding another layer of complexity for financial institutions. The Agriculture Improvement Act of 2018, commonly known as the 2018 Farm Bill, legalized hemp by removing it from the Controlled Substances Act and defining it as cannabis containing no more than 0.3 percent tetrahydrocannabinol (THC) on a dry weight basis. While this created a legal pathway for hemp products, it also introduced a regulatory gap that has been widely exploited.
Hemp-derived cannabinoids such as delta-8 THC, delta-10 THC, and other synthetic or semi-synthetic variants have rapidly expanded in the market. These products are often marketed as legal alternatives to marijuana, yet their legal status remains inconsistent. The DEA’s 2020 Interim Final Rule clarified that synthetically derived tetrahydrocannabinols remain illegal as a controlled substance. However, inconsistent enforcement and differing interpretations across jurisdictions have created uncertainty for businesses and financial institutions alike.
At the state level, regulators are increasingly moving to address these gaps. Throughout 2024 and 2025, multiple states have enacted or proposed restrictions on intoxicating hemp products, including bans on certain THC variants, potency limits, and stricter licensing requirements. This evolving patchwork of rules increases the likelihood that businesses may, intentionally or unintentionally, sell products that are not compliant with their jurisdiction's laws.
For financial institutions, this means the risk is no longer limited to traditional cannabis businesses. Hemp, CBD, and vape retailers may present similar or even heightened risk, particularly when product lines include intoxicating or ambiguously regulated compounds. Without a clear understanding of what is being sold, institutions may unknowingly provide services to businesses operating outside legal boundaries.